Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis
Brachytherapy · 2024
DOI: 10.1016/j.brachy.2023.12.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2024. Verfasst von Kenta Watanabe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Kawasaki Medical School, Kurashiki City, Okayama 701-0192, Japan. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: High-dose-rate brachytherapy (HDR-BT) delivers high-dose radiation to local lesions within a short treatment period. There are no reports of salvage transurethral HDR-BT for biochemical recurrence (BCR) after radical prostatectomy. Thus, we aimed to evaluate the usefulness of salvage transurethral HDR-BT with external beam radiation therapy (EBRT) for anastomotic prostate cancer recurrence. METHODS AND MATERIALS: Patients with postoperative prostate cancer who underwent salvage transurethral HDR-BT with EBRT for anastomotic recurrence at our hospital between January 2002 and July 2009 were retrospectively evaluated. The Kaplan-Meier method was used to estimate biochemical freedom from failure (bFFF), cause-specific survival (CSS), and overall survival (OS) rates. RESULTS: Nine patients were included in this study. The median follow-up period and age were 13.1 (range 4.3-18.4) years and 67 (range 63-78) years, respectively. The dose of HDR-BT ranged from 13 to 24 Gy per 2 to 5 fractions, while that of EBRT ranged from 30 to 44 Gy per 15 to 22 fractions. The 1-year, 5-year, and 10-year bFFF rates were 77.8%, 41.7%, and 13.9%, respectively. The 10-year and 15-year CSS rates were 100% each. The 10-year and 15-year OS rates were 100% and 64.3%, respectively. Six patients were diagnosed with BCR. Two patients experienced Grade 3 hematuria as a late adverse event. There was no exacerbation of urinary incontinence. CONCLUSIONS: No prostate cancer-related deaths were observed, even after a long-term follow-up. Salvage transurethral HDR-BT after radical prostatectomy is safe and feasible and may be a useful treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Kawasaki Medical School, Kurashiki City, Okayama 701-0192, Japan.
- Department of Radiology, Kawasaki Medical School, Kurashiki City, Okayama 701-0192, Japan. Electronic address: kamitani@med.kawasaki-m.ac.jp.
- Department of Urology, Kawasaki Medical School, Kurashiki City, Okayama 701-0192, Japan.
Zitieren
APA
Watanabe, K., Kamitani, N., Ikeda, N., Kawata, Y., Tokiya, R., Hayashi, T., Miyaji, Y., Tamada, T., & Katsui, K. (2024). Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis. Brachytherapy. https://doi.org/10.1016/j.brachy.2023.12.004
Vancouver
Watanabe K, Kamitani N, Ikeda N, Kawata Y, Tokiya R, Hayashi T, et al. Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis. Brachytherapy. 2024. doi:10.1016/j.brachy.2023.12.004
BibTeX
@article{Watanabe2024,
author = {Watanabe, Kenta and Kamitani, Nobuhiko and Ikeda, Naoki and Kawata, Yujiro and Tokiya, Ryoji and Hayashi, Takafumi and Miyaji, Yoshiyuki and Tamada, Tsutomu and Katsui, Kuniaki},
title = {Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis},
journal = {Brachytherapy},
year = {2024},
doi = {10.1016/j.brachy.2023.12.004}
}
EUVIMED